Catharine H Clark

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8276398/publications.pdf

Version: 2024-02-01

88	5,097	159585 30	88630 70
papers	citations	h-index	g-index

88	88	88	5371
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a heterogeneous phantom to measure range in clinical proton therapy beams. Physica Medica, 2022, 93, 59-68.	0.7	3
2	The 3rd ESTRO-EFOMP core curriculum for medical physics experts in radiotherapy. Radiotherapy and Oncology, 2022, 170, 89-94.	0.6	11
3	SEAFARER â€“ A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. Radiotherapy and Oncology, 2022, 171, 121-128.	0.6	6
4	Volumetric modulated arc therapy (VMAT): a review of clinical outcomesâ€”what is the clinical evidence for the most effective implementation?. British Journal of Radiology, 2022, 95, .	2.2	17
5	An end-to-end assessment on the accuracy of adaptive radiotherapy in an MR-linac. Physics in Medicine and Biology, 2021, 66, 055021.	3.0	11
6	In reply to the letter to the editor: â€œIn reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapyâ€• Radiotherapy and Oncology, 2021, 155, e22-e23.	0.6	0
7	Towards an updated ESTRO-EFOMP core curriculum for education and training of medical physics experts in radiotherapy â€“ A survey of current education and training practice in Europe. Physica Medica, 2021, 84, 65-71.	0.7	8
8	Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. Radiotherapy and Oncology, 2021, 159, 106-111.	0.6	21
9	Clinical use, challenges, and barriers to implementation of deformable image registration in radiotherapy â€“ the need for guidance and QA tools. British Journal of Radiology, 2021, 94, 20210001.	2.2	7
10	Quantification of the uncertainties within the radiotherapy dosimetry chain and their impact on tumour control. Physics and Imaging in Radiation Oncology, 2021, 19, 33-38.	2.9	2
11	Professional practice changes in radiotherapy physics during the COVID-19 pandemic. Physics and Imaging in Radiation Oncology, 2021, 19, 25-32.	2.9	5
12	Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer. Physics and Imaging in Radiation Oncology, 2021, 20, 46-50.	2.9	2
13	IAEA methodology for on-site end-to-end IMRT/VMAT audits: an international pilot study. Acta OncolÃ³gica, 2020, 59, 141-148.	1.8	9
14	Grand challenges for medical physics in radiation oncology. Radiotherapy and Oncology, 2020, 153, 7-14.	0.6	33
15	Multivariate log file analysis for multi-leaf collimator failure prediction in radiotherapy delivery. Physics and Imaging in Radiation Oncology, 2020, 15, 72-76.	2.9	8
16	Automatic evaluation of contours in radiotherapy planning utilising conformity indices and machine learning. Physics and Imaging in Radiation Oncology, 2020, 16, 149-155.	2.9	7
17	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. Radiotherapy and Oncology, 2020, 150, 30-39.	0.6	53
18	Comparing Proton to Photon Radiotherapy Plans: UK Consensus Guidance for Reporting Under Uncertainty for Clinical Trials. Clinical Oncology, 2020, 32, 459-466.	1.4	16

#	Article	IF	Citations
19	Multi-institutional dosimetric delivery assessment of intracranial stereotactic radiosurgery on different treatment platforms. Radiotherapy and Oncology, 2020, 147, 153-161.	0.6	10
20	Tissue mimicking materials for imaging and therapy phantoms: a review. Physics in Medicine and Biology, 2020, 65, .	3.0	74
21	Adapting training for medical physicists to match future trends in radiation oncology. Physics and Imaging in Radiation Oncology, 2019, 11, 71-75.	2.9	6
22	Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. Clinical Oncology, 2019, 31, 611-620.	1.4	12
23	Thermoluminescence measurements of eye-lens dose in a multi-centre stereotactic radiosurgery audit. Radiation Physics and Chemistry, 2019, 155, 75-81.	2.8	5
24	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	13.7	697
25	Novel methodologies for dosimetry audits: Adapting to advanced radiotherapy techniques. Physics and Imaging in Radiation Oncology, 2018, 5, 76-84.	2.9	18
26	The role of dosimetry audit in achieving high quality radiotherapy. Physics and Imaging in Radiation Oncology, 2018, 5, 85-87.	2.9	21
27	Remote beam output audits: A global assessment of results out of tolerance. Physics and Imaging in Radiation Oncology, 2018, 7, 39-44.	2.9	19
28	OC-0611: Modelling the clinical impact of machine specific dose variations on outcome using national data. Radiotherapy and Oncology, 2018, 127, S322.	0.6	0
29	A national dosimetry audit for stereotactic ablative radiotherapy in lung. Radiotherapy and Oncology, 2017, 122, 406-410.	0.6	31
30	Characterisation of a plastic scintillation detector to be used in a multicentre stereotactic radiosurgery dosimetry audit. Radiation Physics and Chemistry, 2017, 140, 373-378.	2.8	19
31	National audit of a system for rectal contact brachytherapy. Physics and Imaging in Radiation Oncology, 2017, 1, 1-5.	2.9	7
32	The role of dosimetry audit in lung SBRT multi-centre clinical trials. Physica Medica, 2017, 44, 171-176.	0.7	32
33	Adaptation and validation of a commercial head phantom for cranial radiosurgery dosimetry end-to-end audit. British Journal of Radiology, 2017, 90, 20170053.	2.2	23
34	Challenges in calculation of the gamma index in radiotherapy â€“ Towards good practice. Physica Medica, 2017, 36, 1-11.	0.7	121
35	Radiotherapy reference dose audit in the United Kingdom by the National Physical Laboratory: 20 years of consistency and improvements. Physics and Imaging in Radiation Oncology, 2017, 3, 21-27.	2.9	16
36	Feasibility study of silica bead thermoluminescence detectors (TLDs) in an external radiotherapy dosimetry audit programme. Radiation Physics and Chemistry, 2017, 141, 251-256.	2.8	5

#	Article	IF	Citations
37	A virtual dosimetry audit â€“ Towards transferability of gamma index analysis between clinical trial QA groups. Radiotherapy and Oncology, 2017, 125, 398-404.	0.6	12
38	1st European Congress of Medical Physics September 1â€“4, 2016; Medical Physics innovation and vision within Europe and beyond. Physica Medica, 2017, 41, 1-4.	0.7	0
39	A multi-centre analysis of radiotherapy beam output measurement. Physics and Imaging in Radiation Oncology, 2017, 4, 39-43.	2.9	11
40	The use of log file analysis within VMAT audits. British Journal of Radiology, 2016, 89, 20150489.	2.2	19
41	EP-1935: Impact of standardised codes of practice and related audit on radiotherapy dosimetry over 20 years. Radiotherapy and Oncology, 2016, 119, S918.	0.6	0
42	Changes in Patterns of Intensity-modulated Radiotherapy Verification and Quality Assurance in the UK. Clinical Oncology, 2016, 28, e28-e34.	1.4	17
43	The role of complexity metrics in a multi-institutional dosimetry audit of VMAT. British Journal of Radiology, 2016, 89, 20150445.	2.2	34
44	Current status of cranial stereotactic radiosurgery in the UK. British Journal of Radiology, 2016, 89, 20150452.	2.2	22
45	Feasibility of using glass-bead thermoluminescent dosimeters for radiotherapy treatment plan verification. British Journal of Radiology, 2015, 88, 20140804.	2.2	10
46	Expanding the scientific role of medical physics in radiotherapy: Time to act. Radiotherapy and Oncology, 2015, 117, 401-402.	0.6	15
47	Evaluation of Gafchromic EBT-XD film, with comparison to EBT3 film, and application in high dose radiotherapy verification. Physics in Medicine and Biology, 2015, 60, 8741-8752.	3.0	81
48	Radiotherapy dosimetry audit: three decades of improving standards and accuracy in UK clinical practice and trials. British Journal of Radiology, 2015, 88, 20150251.	2.2	50
49	A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. British Journal of Cancer, 2015, 112, 32-38.	6.4	29
50	Inter-departmental dosimetry audits â€“ development of methods and lessons learned. Journal of Medical Physics, 2015, 40, 183.	0.3	10
51	Global Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1242-1249.	0.8	44
52	A multi-institutional dosimetry audit of rotational intensity-modulated radiotherapy. Radiotherapy and Oncology, 2014, 113, 272-278.	0.6	49
53	Glass beads and Ge-doped optical fibres as thermoluminescence dosimeters for small field photon dosimetry. Physics in Medicine and Biology, 2014, 59, 6875-6889.	3.0	19
54	Radiation therapy quality assurance in clinical trials â€“ Global harmonisation group. Radiotherapy and Oncology, 2014, 111, 327-329.	0.6	55

#	Article	IF	Citations
55	Energy response of glass bead TLDs irradiated with radiation therapy beams. Radiation Physics and Chemistry, 2014, 104, 208-211.	2.8	18
56	Low-cost commercial glass beads as dosimeters in radiotherapy. Radiation Physics and Chemistry, 2014, 97, 95-101.	2.8	48
57	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. Oral Oncology, 2014, 50, 1089-1097.	1.5	21
58	Preliminary investigations of two types of silica-based dosimeter for small-field radiotherapy. Radiation Physics and Chemistry, 2014, 104, 139-144.	2.8	3
59	Doseâ€“response analysis of parotid gland function: What is the best measure of xerostomia?. Radiotherapy and Oncology, 2013, 106, 341-345.	0.6	24
60	A comparison of the gamma index analysis in various commercial IMRT/VMAT QA systems. Radiotherapy and Oncology, 2013, 109, 370-376.	0.6	130
61	Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for 18F-FDG-PET-guided dose escalation in oropharyngeal cancer: A planning study. Medical Dosimetry, 2013, 38, 18-24.	0.9	7
62	A methodology for dosimetry audit of rotational radiotherapy using a commercial detector array. Radiotherapy and Oncology, 2013, 108, 78-85.	0.6	34
63	Development of a novel treatment planning test for credentialing rotational intensity-modulated radiotherapy techniques in the UK. British Journal of Radiology, 2013, 86, 20120315.	2.2	12
64	A critical evaluation of the PTW 2Dâ€ARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification. Journal of Applied Clinical Medical Physics, 2013, 14, 274-292.	1.9	47
65	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology, The, 2012, 13, 43-54.	10.7	303
66	Dose-Escalated Intensity-Modulated Radiotherapy Is Feasible and May Improve Locoregional Control and Laryngeal Preservation in Laryngo-Hypopharyngeal Cancers. International Journal of Radiation Oncology Biology Physics, 2012, 82, 539-547.	0.8	40
67	Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the PARSPORT Phase III trial. Radiotherapy and Oncology, 2012, 104, 205-212.	0.6	73
68	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncology, The, 2011, 12, 127-136.	10.7	1,407
69	Volumetric modulated arc therapy: a review of current literature and clinical use in practice. British Journal of Radiology, 2011, 84, 967-996.	2.2	503
70	Intensity-modulated Radiotherapy Allows Escalation of the Radiation Dose to the Pelvic Lymph Nodes in Patients with Locally Advanced Prostate Cancer: Preliminary Results of a Phase I Dose Escalation Study. Clinical Oncology, 2010, 22, 236-244.	1.4	38
71	Impact of Intrafraction Motion on TCP and Rectal NTCP Values in Patients Receiving IG-IMRT for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, S363-S364.	0.8	2
72	Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. British Journal of Radiology, 2009, 82, 585-594.	2.2	43

#	Article	IF	Citations
73	Dosimetry audit for a multi-centre IMRT head and neck trial. Radiotherapy and Oncology, 2009, 93, 102-108.	0.6	52
74	A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiotherapy and Oncology, 2007, 85, 36-41.	0.6	53
75	Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: Acute toxicity results of a phase I study. Radiotherapy and Oncology, 2007, 85, 58-63.	0.6	50
76	Target Volume Definition for Head and Neck Intensity Modulated Radiotherapy: Pre-clinical Evaluation of PARSPORT Trial Guidelines. Clinical Oncology, 2007, 19, 604-613.	1.4	32
77	Intensity Modulated Radiotherapy Improves Target Coverage and Parotid Gland Sparing When Delivering Total Mucosal Irradiation in Patients With Squamous Cell Carcinoma of Head and Neck of Unknown Primary Site. Medical Dosimetry, 2007, 32, 188-195.	0.9	24
78	A quantitative study of IMRT delivery effects in commercial planning systems for the case of oesophagus and prostate tumours. British Journal of Radiology, 2006, 79, 401-408.	2.2	5
79	Intensity Modulated Radiotherapy in Cancer of the Larynx. , 2006, , 335-344.		0
80	Dose to Bone Marrow Using IMRT Techniques in Prostate Cancer Patients. Strahlentherapie Und Onkologie, 2005, 181, 172-178.	2.0	33
81	The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiotherapy and Oncology, 2005, 77, 241-246.	0.6	103
82	Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiotherapy and Oncology, 2004, 70, 189-198.	0.6	55
83	Verification of patient position and delivery of IMRT by electronic portal imaging. Radiotherapy and Oncology, 2004, 73, 339-347.	0.6	23
84	Implementation of IMRT in the radiotherapy department. British Journal of Radiology, 2003, 76, 850-856.	2.2	24
85	In regard to Lee et al., IJROBP 2002;53:630â€“637. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1150.	0.8	1
86	IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. Journal of Applied Clinical Medical Physics, 2002, 3, 273-284.	1.9	27
87	The use of electronic portal imaging to verify patient position during intensity-modulated radiotherapy delivered by the dynamic MLC technique. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1225-1234.	0.8	21
88	IMRT clinical implementation: Prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator. Journal of Applied Clinical Medical Physics, 2002, 3, 273.	1.9	29